Author: Ashleigh Brissett

In a significant stride towards combating lung cancer, the upcoming National Lung Cancer Screening Program (NLCSP) is set to launch in July 2025.

This initiative was the main topic at the recent monthly AH&MRC Updates meeting, where NSW ACCHOs had the opportunity to hear from guest presenters from Heart of Australia and NACCHO about the program’s rollout. 

Mobile CT Scanners on the Move 

Heart of Australia shared updates on the proposed sites for mobile CT scanners, which will play a crucial role in the NLCSP. They detailed the screening route planning and engagement activities, describing the equity lens they are trying to apply to determine these sites. This approach is aimed at ensuring the screening services reach communities most in need. 

Valuable Insights from ACCHO Leaders 

A big thank you goes out to the ACCHO CEOs who attended the consultation meeting. Your feedback given to the presenters and the Commonwealth Department of Health and Aged Care who were also in attendance, is instrumental in shaping the decisions regarding the mobile screening sites in NSW.  

Eligibility for the NLCSP 

The rollout of the NLCSP will involve engaging with NSW ACCHOs to discuss smoking and vaping behaviours being seen in your communities. These are key factors in determining eligibility for lung cancer screening. To better understand these behaviours, the AH&MRC’s Public Health Team is developing a survey to assess the impact of recent vaping legislation changes on community smoking and vaping habits. Stay tuned for more updates!   

Addressing Training and Resource Gaps 

The AH&MRC Member Engagement team is also conducting a gap analysis to identify training and resource needs related to smoking and vaping cessation among healthcare workers in ACCHOs. AH&MRC aims to ensure that our member services workforce have access to the training they need to support the community through the rollout of the NLCSP. For further information, please see “What do ACCHOs need to support community members on their QUIT journey?” 

Further Opportunity for Input from NSW ACCHOs 

NACCHO is seeking input from ACCHOs on resources being developed for the NLCSP and broader cancer screening discussions. If you have insights or wish to discuss further, please reach out to Sarah.McDermott@naccho.org.au. 

Many of you will know the “Blue Book” which is a Personal Health Record for NSW children aged 0-5 years. 

NSW Health is looking for Health Care Providers to participate in a virtual interview (45-60 minutes) to better understand how eHealth NSW can develop a digital version of the Blue Book that will integrate into the current workflow of healthcare workers.  

This is an opportunity for the ACCHO sector to have input into this new resource so that it meets the needs of your workflow and is culturally safe for your communities.  

If you’re interested in being a participant in this important project, register here. 

For additional information about the project, you can contact:  

Kerin Hibbard– kerin.hibbard@health.nsw.gov.au or  

Abbey Wiseman – abbey.wiseman@health.nsw.gov.au 

Back in April, we shared an alert from NSW Health about rising cases of pertussis (whooping cough). Unfortunately, the trend continues, with NSW experiencing its highest pertussis rates in 15 years. Infants are at risk of severe illness and even death from pertussis.  

 Here’s how we can stay ahead and protect our at-risk bubs:  

• Timely vaccinations—ensure our infants receive their vaccines on schedule 

• Vaccinate during pregnancy—pregnant women should receive the pertussis vaccine between 20-32 weeks  

• Keep family members protected—parents, grandparents, family and caregivers in regular contact with infants should be up to date with vaccinations  

• Early testing and treatment—continue considering pertussis as a diagnosis for anyone presenting with a persistent cough  

 For more information and the latest GP alert on pertussis, visit the NSW Health Infectious disease alerts page.  

There is currently a shortage of the HIV PrEP combination tenofovir disoproxil and emtricitabine until November 2024. 

The TGA has approved a limited supply of an S19A combination product.  

NSW Health has been able to secure a sufficient quantity of this product for the current shortage duration. 

If your patients are having difficulty accessing a supply of HIV PrEP, contact the Sexual Health Info Link (SHIL) on 1800 451 624 for advice. Encourage alternative prevention methods such as condoms and lube in the meantime. 

For further information and advice regarding the shortage situation you can also visit the ASHM website.